New method to enhance adoptive T-cell therapies

09-Jun-2017 - Germany

Medigene AG announces that a scientific article on a method to enhance adoptive T cell therapies has been published in the current issue of "Cancer Research". The research results show how adoptive T cell therapies can be improved by optimizing the T cells' effector functions without changing their specificity.

Inherent intermediate-to-low avidity T-cell receptors (TCR) that develop during the natural course of immune responses may not allow sufficient activation for tumor elimination, making the majority of T cells suboptimal for adoptive T cell therapy (ATT). TCR affinity enhancement has been implemented to provide stronger T cell activity but carries the risk of creating undesired cross-reactivity leading to potential serious adverse effects in clinical application. The researchers demonstrated in the now published article that complementing low-avidity T cells recognizing a naturally processed and presented tumor-associated antigen by co-expression of a chimeric PD-1:28 receptor increases effector function to levels seen with high-avidity T cells of identical specificity.

Prof. Dr. Elfriede Nössner, Head of Immunoanalytics - Research Group Tissue Control of Immunocytes and Core Facility at the Helmholtz Zentrum München, and senior author of the publication, explains: "Enhanced T cells combined with checkpoint blockade might be a beneficial combination for therapeutic strategies. Altogether, the supportive effects of adding PD-1:28 to T-cell function makes it an attractive tool for adoptive T-cell therapy."

Prof. Dr. Dolores J. Schendel, CEO and CSO of Medigene AG and co-author of the publication, adds: "Upgrading the function of low-avidity T cells without changing the TCR affinity will allow a large arsenal of low-avidity T cells previously thought to be therapeutically inefficient to be considered for adoptive T-cell therapy. We are actively considering these results within Medigene for the development of future TCR therapies and are excited about the prospects of this approach"

The results have been generated in a research alliance of scientists from nine German academic institutions and scientists from Medigene AG.

Original publication

Ramona Schlenker et al.; "Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy"; Cancer Research; 2017

https://www.bionity.com/en/news/163584/new-method-to-enhance-adoptive-t-cell-therapies.html

Original publication

Ramona Schlenker et al.; "Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy"; Cancer Research; 2017

Topics

cell therapies T-cell therapies T-cell receptors T cells adoptive T cell therapy

Show all

Organizations

MediGene Helmholtz Zentrum München